Top 3 Compounding Updates

Always a topic of substantial interest to practicing veterinarians, compounding continues to be one of AVMA’s high-priority issues we advocate for our members. Here is a short list of some particularly current compounding topics.

• AVMA has a newly updated compounding web page which provides resources for veterinarians. We have a new Frequently Asked Questions for veterinarians. There’s also a link to our compounding brochure.

• There will be no additional court action with regard to the FDA’s injunction against Franck’s Lab Inc. The court has granted the joint motion to vacate and dismiss as moot. Franck’s is said to have been acquired by another company, thereby rendering the court case moot since it’s been reported that Franck’s no longer owns or operates the facilities in question. Having closure on this court case would have added context on federal enforcement of compounding from bulk/raw ingredients, although there’d still be no clear federal delineation of “compounding” versus “manufacturing.”

• Recent meningitis concerns in human medicine have yielded Congressional interest in compounding. This means that Congress could consider legislation on compounding which could affect both human and veterinary medicine. Certainly our Governmental Relations Division remains active on Capitol Hill, and our volunteer leaders on our Council on Biologic and Therapeutic Agents and Clinical Practitioners Advisory Committee continue to stay involved as we assess this situation. Look for more about possible federal legislation on compounding from AVMA as we learn more.

One thought on “Top 3 Compounding Updates

  1. As a veterinary professional, I rely on compounded preparations to provide unique solutions for my patients. I understand that the AVMA is considering a policy that would support only a limited list of bulk APIs for use in compounded prescriptions. This policy would reinforce the FDA’s current misinterpretation of its own guidelines, yield to pressure from the pharmaceutical industry and could ultimately keep me from prescribing compounds made from bulk APIs as I deem necessary in my practice. This would make it harder for me to treat my patients according to their needs and would inevitably lead to unnecessary suffering or death. I would hope that, as an organization that represents my interests, you will not advocate for any action that would make it harder for me to treat my patients as I see fit. Instead of helping to restrict my rights and reduce my options to prescribe compounded medications in a new policy, the AVMA must take a stand to allow me to continue exercising the same rights that physicians enjoy.

    Mark DePaolo, DVM
    AVMA Member ID: 0116207